Depression is a common, devastating illness. Current pharmacotherapies help many
patients, but high rates of a partial response or no response, and the delayed onset of the …

Most currently available antidepressants target monoamine neurotransmitter function.
However, a purely neurotransmitter-based explanation for antidepressant drug action is …

Depression is an episodic form of mental illness characterized by mood state transitions with
poorly understood neurobiological mechanisms. Antidepressants reverse the effects of …

Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more
months after only one or two treatments. Another hallucinogenic drug, esketamine, has …

Basic and clinical studies demonstrate that depression is associated with reduced size of
brain regions that regulate mood and cognition, including the prefrontal cortex and the …

Clinical and preclinical studies have demonstrated that depression, one of the most common
psychiatric illnesses, is associated with reduced levels of neurotrophic factors, including …

Currently available antidepressants have a substantial time lag to induce therapeutic
response and a relatively low efficacy. The development of drugs that addresses these …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …

Clinical brain imaging and postmortem studies provide evidence of structural and functional
abnormalities of key limbic and cortical structures in depressed patients, suggesting that …